Today, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert in the area of neurosurgery, to develop novel technology and methods to treat Central Nervous System (CNS) tumors with Alpha1H.
Alpha1H is effective against a range of solid and haematological tumor cells that commonly metastasize to the CNS. Early studies in rats have shown that infusion of HAMLET into the brain markedly delayed the progression of glioblastomas. Glioblastomas are highly invasive and malignant brain tumours with a poor prognosis, accounting for about 60% of all primary brain tumors. At the time of diagnosis, the tumors are mostly inaccessible to complete surgical removal due to spread of tumor cells from the primary tumor site and there is a lack if efficient, alternative treatments.
As a pioneer in this field, Professor Gill has invented new technologies for drug delivery into the brain and used them successfully in the treatment of neurological diseases and cancers. In this collaboration between Neurochase and Hamlet Pharma, new technology will be developed for delivery of Alpha1H to the leptomeninges for treatment of primary and secondary CNS tumors. The collaboration will primarily explore infusion of Alpha1H in preclinical models in preparation for clinical trials.
Steven Gill said “We are delighted to be collaborating with Hamlet Pharma on this programme. Alpha 1H has shown very promising results to date as a potential treatment for CNS tumors. I am hopeful that by working together we can improve the otherwise poor outcome for patients with CNS tumors”.
“ Combining this novel technology with Alpha1H to explore the treatment of brain tumors is a very exiting prospect”, says Catharina Svanborg, Professor and Chairman of Hamlet Pharma AB.
For more information, contact
Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49
Martin Erixon, CEO of Hamlet Pharma, +46-733 00 43 77
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops new drugs for the treatment and prevention of cancer, based on the discovery of the tumoricidal protein-lipid complex, HAMLET. HAMLET has shown therapeutic efficacy in animal models and effects in clinical proof-of-concept studies. The Alpha1H peptide drug candidate, reproduces the effects of HAMLET and has demonstrated therapeutic efficacy in patients with bladder cancer, where cinical trials are ongoing. Bladder cancer is a common and costly form of cancer, with few successful new treatment options. The company is further exploring the use of Alpha1H for other cancer indications, including brain tumors. In addition, Hamlet Pharma develops BAMLET, which is a HAMLET-like complex formed by bovine α-lactalbumin. Data from animal models show promising effects of local BAMLET treatment against colon cancer.
About Neurochase Limited
Neurochase, founded by Professor Steven Gill, aims to bring transformative targeted therapies to patients with neurological diseases using state of the art technology. The company’s team specialises in creating bespoke therapeutic strategies for the direct delivery of therapies using Convection Enhanced Delivery (CED). Neurochase provides accurate, targeted and safe direct drug delivery to the CNS and develops globally scalable treatment strategies and solutions for the pharmaceutical and biotech industry.
Neurochase Ltd. is a Registered Company Number 12428919. www.neurochase.com